Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen

AIDS

Volumn 14, Issue 2, 2000, Pages

  Casado, Jose L ^a   Hertogs, Kurt ^c   Ruiz, Lidia ^b   Dronda, Fernando ^a   Van Cauwenberge, Anja ^c   Arnó, Albert ^b   Garcia Arata, Isabel ^a   Bloor, Stuart ^d   Bonjoch, Anna ^b   Blazquez, Jesús ^a   Clotet, Bonaventura ^b   Larder, Brendan ^d  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Virco BVBA   (Belgium)

^d Virco UK Ltd   (United Kingdom)

Author keywords

Antiretroviral therapy; Cross resistance; Nevirapine; Non nucleoside reverse transcriptase inhibitors; Rescue regimen; Resistance

Indexed keywords

DELAVIRDINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; COHORT ANALYSIS; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; UNIVERSITY HOSPITAL;

ADULT; COHORT STUDIES; DELAVIRDINE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; MUTATION; NEVIRAPINE; OXAZINES; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 0033994776     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001280-00001     Document Type: Article

References (19)

1. 1. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998, 279:930-937.
2. 2. Tashima K, Staszewski S, Stryker R, et al. A phase III, multicenter, randomized, open-label study to compare the antiretroviral activity and tolerability of efavirenz + indinavir versus EFV + zidovudine + lamivudine versus IDV + ZDV + 3TC at 48 weeks. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 31 January-4 February 1999 [Abstract LB16].
3. 3. Katlama K, Murphy R, Johnson V, et al. The Atlantic study: a randomized open-label study comparing two protease inhibitors-sparing antiretroviral strategies versus a standard PI-containing regimen. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 31 January-4 February 1999 [Abstract 18].
4. 4. De Clerq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998, 38:153-179.
5. 5. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996, 70:7894-7899.
6. 6. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. JVirol 1994, 68:1660-1666.
7. 7. Condra JH, Emini EA, Gotlib L, et al. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother 1992, 36:1441-1446.
8. 8. Miller V, de Bethune MP, Kober A, et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998, 42:3123-3129.
9. 9. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998, 280:78-86.
10. 10. Hertogs K, de Bethune M, Miller V. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
11. 11. Pauwels R, Hertogs K, Kemp S, et al. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis. 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, July 1999 [Abstract 51].
12. 12. Maga G, Amacker M, Ruel N, Hübscher U, Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J Mol Biol 1997, 274:738-747.
13. 13. de long MD, Loewenthal M, Boucher CA, et al. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity. J Infect Dis 1994, 169:1346-1350.
14. 3. AIDS Clinical Trials Group protocol 208. J Infect Dis 1995, 172:1379-1383.
15. 15. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282.1135-1141.
16. 16. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquired Immune Defic Syndr Hum Retrovirol 1995, 8: 141-151.
17. 17. Demeter LM, Meehan PM, Morse G, et al. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquired Immune Defic Syndr Hum Retrovirol 1997, 14: 136-144.
18. 18. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992, 36:2664-2669.
19. 19. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999, 179:1375-1381.